Breast cancer cells need to take up lipids from the extracellular environment in order to continue proliferating, researchers report in a new study. The main protein involved in this process is LIPG, an enzyme found in the cell membrane (the layer that surrounds a cell) and without which tumor cell growth is arrested.
Analyses of more than 500 clinical samples from patients with various kinds of breast tumor reveal that 85% have high levels of LIPG expression.
It was already known that cancer cells require extracellular glucose to grow and that they reprogram their internal machinery to produce greater amounts of lipids (fats). The relevance of this study is that it reveals for the first time that tumor cells must import extracellular lipids to grow.
“This new knowledge related to metabolism could be the Achilles heel of breast cancer,”
explains ICREA researcher and IRB Barcelona group leader Roger Gomis, co-leader of the study together with Joan J. Guinovart, director of IRB Barcelona and professor at the University of Barcelona. Using animal models and cancer cell cultures, the scientists have demonstrated that blocking of LIPG activity arrests tumor growth.
3-D structure of a LIPG protein. IRB Barcelona
“What is promising about this new therapeutic target is that LIPG function does not appear to be indispensable for life, so its inhibition may have fewer side effects than other treatments,”
explains the first author of the study, Felipe Slebe, who was funded by a “la Caixa” International PhD fellowship. Guinovart comments that, “because LIPG is a membrane protein, it is potentially easier to design a pharmacological agent to block its activity.”
LIPG has “many virtues” as a target.
“If a drug were found to block its activity, it could be used to develop more efficient chemotherapy treatments that are less toxic than those currently available,” says Gomis.
The scientists are now looking into international collaborations in order to develop LIPG inhibitors.